Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OFIRMEV vs AMCILL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Infections of the respiratory tract,Infections of the genitourinary tract,Meningitis,Septicemia,Endocarditis,Gastrointestinal infections,Prophylaxis of bacterial endocarditis
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Partially metabolized by hydrolysis; primarily excreted unchanged in urine via renal tubular secretion and glomerular filtration.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Renal: 60-80% unchanged; biliary: less than 10%; fecal: small amount.
10-25% bound to albumin at therapeutic concentrations.
20% bound, primarily to albumin.
0.8-1.0 L/kg. Indicates distribution into total body water.
0.3 L/kg; indicates distribution into extracellular fluid.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Oral: 50-70% (variable, reduced by food); IM: nearly 100%.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
For Cr Cl 30-50 m L/min: administer every 12 hours; for Cr Cl 10-29 m L/min: administer every 18-24 hours; for Cr Cl <10 m L/min: administer every 24 hours.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
No specific adjustments recommended for Child-Pugh A or B; use caution in severe hepatic impairment (Child-Pugh C) with monitoring.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Children >1 month: 25-50 mg/kg/day orally divided every 8 hours; for severe infections, up to 100 mg/kg/day IV divided every 6 hours. Maximum dose: 2 g/day.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
No specific dose adjustment required; monitor renal function and adjust based on creatinine clearance.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
No FDA black box warning.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Hypersensitivity reactions including anaphylaxis,Clostridioides difficile-associated diarrhea,Superinfection,Risk of seizures with high doses or renal impairment,Use caution in patients with mononucleosis (high risk of rash)
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Hypersensitivity to ampicillin, penicillins, or any component of the formulation,Infections caused by beta-lactamase-producing organisms
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Food does not significantly affect absorption; may be taken with or without meals. Avoid alcohol: may increase risk of disulfiram-like reaction (rare).
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearly needed; potential for altered gut flora and diarrhea in neonate.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
Ampicillin is excreted in breast milk in low concentrations (M/P ratio approximately 0.2). Compatible with breastfeeding; monitor infant for diarrhea or rash.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
Increased renal clearance during pregnancy may require higher doses to maintain therapeutic levels. Standard dosing is usually adequate for most indications; consider monitoring serum levels in severe infections.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
AMCILL (ampicillin) is a broad-spectrum penicillinase-sensitive penicillin. Use caution in patients with renal impairment; dose adjustment required for Cr Cl <30 m L/min. Monitor for hypersensitivity reactions, especially in patients with cephalosporin allergy. IV administration may cause phlebitis; rotate infusion sites. Not effective against penicillinase-producing organisms including Staphylococcus aureus.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
Take exactly as prescribed; complete full course even if you feel better.,Notify your doctor if you develop rash, hives, or difficulty breathing.,May cause diarrhea; contact your doctor if severe or bloody.,Take with a full glass of water; avoid acidic beverages like orange juice.,Inform your doctor if you are pregnant, breastfeeding, or taking oral contraceptives (ampicillin may reduce efficacy).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OFIRMEV vs AMCILL, answered by our medical review team.
OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. AMCILL is a Penicillin Antibiotic that works by Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OFIRMEV and AMCILL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. The standard adult dose of AMCILL is: 250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OFIRMEV and AMCILL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. AMCILL is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.